** Shares of drugmaker Avadel Pharmaceuticals AVDL.O up 3% at $8.15 premarket
** Co posts Q4 net product revenue of $50.4 million on sales of its muscle weakness drug, Lumryz; above analysts' average estimate of $50.03 million, according to data compiled by LSEG
** Co reiterates 2025 forecast net product revenue of $240 million to $260 million, compared with estimates of $251.17 million
** AVDL has fallen 40% in the last 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。